Clinically Aggressive Pseudomyxoma Peritonei: A Variant of a Histologically Indolent Process

Journal of Surgical Oncology

Volumn 86, Issue 1, 2004, Pages 10-15

  Mohamed, Faheez ^a   Gething, Sue ^b   Haiba, Moutaz ^b   Brun, Erwin A ^b   Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Cytoreductive surgery; Disseminated peritoneal adenomucinosis; Mucinous adenocarcinoma; Pseudomyxoma peritonei syndrome

Indexed keywords

MUCIN 1; MUCIN 2;

ADENOCARCINOMA; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DISSEMINATED CANCER; DISSEMINATED PERITONEAL ADENOMUCINOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUCINOSIS; MUCINOUS CARCINOMA; PERITONEAL MUCINOUS CARCINOMA; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL;

ADULT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CA-15-3 ANTIGEN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; MUCINS; NEOPLASM RECURRENCE, LOCAL; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; REOPERATION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURGICAL PROCEDURES, OPERATIVE;

EID: 1842852114     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20038     Document Type: Article

References (15)

1. Sugarbaker PH, Ronnett BM, Archer A, et al.: Pseudomyxoma peritonei syndrome. Adv Surg 1996;30:233-280.
2. Ronnett BM, Zahn CM, Kurman RJ, et al.: Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995;19:1390-1408.
3. Ronnett BM, Yan H, Kurman RJ, et al.: Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001;92:85-91.
4. Yan H, Pestieau SR, Shmookler BM, et al.: Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation. Mod Pathol 2001;14:164-171.
5. Ajioka Y, Allison LJ, Jass JR: Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol 1996;49:560-564.
6. Hiraga Y, Tanaka S, Haruma K, et al.: Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998;55:307-319.
7. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995;221:29-42.
8. Jacquet P, Sugarbaker PH: Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49-58.
9. Aoki R, Tanaka S, Haruma K, et al.: MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinoma. Dis Colon Rectum 1998;41:1262-1272.
10. Yonezawa S, Sato E: Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 1997;47:813-830.
11. Zotter SHP, Lossnitzer A, Mooi WJ, et al.: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988;11:55-101.
12. Manne U, Weiss HL, Grizzle WE: Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. Clin Cancer Res 2000;6:4017-4025.
13. O'Connell JT, Tomlinson JS, Roberts AA, et al.: Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol 2002;161:551-564.
14. Sugarbaker PH, Jablonski KA: Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124-132.
15. Zoetmulder FA, Sugarbaker PH: Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur J Cancer 1996;32A:1727-1733.